Biosimilars | Access & Reimbursement | US/EU | 2023
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential reimbursement. Although biosimilars such as Pfizer’s Inflectra and Retacrit are available both in Europe and the United States, their success may vary because of regional differences in the drivers of and barriers to biosimilar uptake. As such, it is necessary for biosimilars developers and manufacturers of branded biologics to understand which factors influence payer decisions regarding biosimilars.
Questions answered:
- What are payers’ perspectives on the drivers of and barriers to biosimilars uptake?
- What factors influence which biosimilars are preferred on formularies in the United States?
- How do payers choose among multiple biosimilars of the same brand in the EU?
- What strategies do payers use to manage biosimilars?
- What expectations do payers have for biosimilars discounts?
- How would the availability of biosimilars influence the pricing of emerging agents?
- Will payer strategies for biosimilars differ between therapeutic specialties?
- Has COVID-19 affected the use or coverage of biosimilars?
Key markets covered:
- France
- Germany
- Italy
- Spain
- United Kingdom
- United States
Key companies mentioned:
- Amgen
- Biocon
- Biogen
- Boehringer Ingelheim
- Celltrion
- Eli Lilly
- Janssen
- Johnson & Johnson
- Merck & Co.
- Mundipharma
- Viatris (Mylan)
- Novartis
- Pfizer
- Roche
- Samsung Bioepis
- Sandoz
- Sanofi
- Teva
Key drugs mentioned:
- Admelog / Insulin Lispro Sanofi
- Aranesp
- Avastin
- Avsola
- Basaglar / Abasaglar
- Benepali
- Binocrit
- Enbrel
- Flixabi
- Fulphila
- Herceptin
- Herzuma
- Hulio
- Humalog
- Humira
- Inflectra
- Kanjinti
- Lantus
- Levemir
- Mvasi
- Neulasta
- Neupogen
- Nivestim / Nivestym
- NovoLog / NovoRapid
- Nyvepria
- Ogivri
- Ontruzant
- Procrit / Epogen
- Remicade
- Remsima
- Retacrit
- Riabni
- Rituxan / MabThera
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Zarzio / Zarxio
- Ziextenzo
- Zirabev
Related Market Assessment Reports
Report
Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…
